EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease

Brooke Maracle, Steven Quan, Patrick Hamilton, Asma Shaikh, Deepan Hazra, Diane L Lorenzetti, Stephanie L Gold iD, Maitreyi Raman iD, Joëlle St-Pierre

Alimentary Pharmacology & Therapeutics · 2026-01 · 63 (1) · 17-39

DOI: 10.1111/apt.70485 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 30.11.2025. Verfasst von Brooke Maracle und 8 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Ca…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity and metabolic disease are increasingly prevalent in patients with inflammatory bowel disease (IBD) and can influence disease activity and treatment outcomes. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are effective for weight loss and metabolic control, yet their safety and effects in IBD remain uncertain as patients with IBD have been excluded from pivotal trials.

Aims

To systematically evaluate the weight‐related, metabolic, IBD‐specific, and safety outcomes of GLP‐1 receptor agonists in adults with IBD.

Methods

We conducted a systematic review according to PRISMA guidelines (PROSPERO CRD42025628850). We searched MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov to 9 September 2025 for studies evaluating GLP‐1 RAs in adults with IBD. Primary outcomes were weight‐related measures. Secondary outcomes included metabolic parameters, IBD activity, and safety. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists.

Results

We included 14 studies of which 13 were retrospective cohort studies. Ten reported significant reductions in body weight, BMI, or percent weight loss. Four demonstrated improvements in metabolic markers, including decreased haemoglobin A1c and favourable lipid changes. Across multiple datasets, GLP‐1 RA use was not associated with increased IBD exacerbations. Several large registries reported reduced risks of corticosteroid use, hospitalisation and surgery among GLP‐1 RA users. Adverse events were primarily gastrointestinal, consistent with non‐IBD populations.

Conclusion

GLP‐1 RAs appear to be well tolerated in patients with IBD, with observational evidence suggesting potential associations with improved weight, metabolic, and disease‐related outcomes. Prospective, IBD‐specific studies are required to confirm safety, clarify mechanisms, and define optimal patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHumansWeight LossTreatment OutcomeAdultObesity

Stichwörter der Autor:innen

Crohn's diseaseGLP‐1 receptor agonistsinflammatory bowel diseasemetabolic syndromeobesitytype 2 diabetesulcerative colitisweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • IBD Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Health Sciences Library, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Stephanie L Gold, Maitreyi Raman

Zitieren

APA

Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D. L., Gold, S. L., Raman, M., & St-Pierre, J. (2026). Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 63(1), 17-39. https://doi.org/10.1111/apt.70485

Vancouver

Maracle B, Quan S, Hamilton P, Shaikh A, Hazra D, Lorenzetti DL, et al. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2026;63(1):17-39. doi:10.1111/apt.70485

BibTeX
@article{Maracle2026,
  author = {Maracle, Brooke and Quan, Steven and Hamilton, Patrick and Shaikh, Asma and Hazra, Deepan and Lorenzetti, Diane L and Gold, Stephanie L and Raman, Maitreyi and St-Pierre, Joëlle},
  title = {Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {1},
  pages = {17--39},
  doi = {10.1111/apt.70485}
}
Kostenlos starten →